BioPortfolio

Share

BioPortfolio

 •  August 1

Summary The purpose of this study is to assess the safety and efficacy of vedolizumab intravenous (IV) infusion as induction treatment in Chinese participants withmoderately to severely active Crohn's disease (CD) at Week 10. Description The drug being tested in this study is called vedolizumab. Vedolizumab will be administered as an intravenous...

BioPortfolio

 •  July 10

Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ... Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza...

BioPortfolio

 •  July 2

Delivery of the Report will take 23 working days once order is placed. The Global Peripheral IV Catheter Market Research Report Forecast 20172022 is a valuable source of insightful data for business strategists. It provides the Peripheral IV Catheter industry overview with growth analysis and historical futuristic cost, revenue, demand and supply...

BioPortfolio

 •  June 20

Infuseon Therapeutics and OncoSynergy are teaming up to evaluate the latter’s monoclonal pan-CD29 antibody OS2966, delivered using Infuseon’s Cleveland Multiport Catheter™ (CMC), for the potential treatment of glioblastoma. The firms’ strategic alliance aims to establish proof of concept that OS2966 can be delivered directly to the brain using the...